Literature DB >> 19347989

Plasma fractionation, a useful means to improve national transfusion system and blood safety: Iran experience.

A M Cheraghali1, H Abolghasemi.   

Abstract

In 1974, the government of Iran established Iranian Blood Transfusion Organization (IBTO) as national and centralized transfusion system. Since then donations of blood may not be remunerated and therapy with blood and its components are free of charges for all Iranian patients. Donations are meticulously screened through interviewing donors and lab testing the donations using serological methods. Currently, Iranian donors donate 1735 00 units of blood annually (donation index: 25/1000 population). Implementation of a highly efficient donor selection programme, including donors interview, establishment of confidential unit exclusion programme and laboratory screening of donated bloods by IBTO have led to seroprevalence rates of 0.41%, 0.12% and 0.004% for HBV, HCV and HIV in donated bloods respectively. Since 2004, IBTO has initiated a programme to enter into a contract fractionation agreement for the surplus of recovered plasma produced in its blood collecting centres. Although IBTO has used this project as a mean to improve national transfusion system through upgrading its quality assurance systems, IBTO fractionation project has played a major role in improving availability of plasma-derived medicines in Iran. During 2006-2007, this project furnished the Iran market with 44% and 14% of its needs to the intravenous immunoglobulin and albumin, respectively. Iranian experience showed that contract fractionation of plasma in countries with organized centralized transfusion system, which lack national plasma fractionation facility, in addition to substantial saving on national health resource and enhancing availability of plasma-derived medicines, could serve as a useful means to improve national blood safety profile.

Entities:  

Mesh:

Year:  2009        PMID: 19347989     DOI: 10.1111/j.1365-2516.2008.01936.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  7 in total

1.  Comparison of the prevalence of major transfusion-transmitted infections among Iranian blood donors using confidential unit exclusion in an Iranian population: Transfusion-transmitted infections among Iranian blood donors.

Authors:  Azadeh Omidkhoda; Ahmad Gharehbaghian; Mostafa Jamali; Naser Ahmadbeigi; Seyed Mahmoud Hashemi; Abas Rahimi; Masoud Soleimani
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

2.  Blood safety concerns in the Eastern Mediterranean region.

Authors:  Abdol Majid Cheraghali
Journal:  Hepat Mon       Date:  2011-06       Impact factor: 0.660

3.  Initial Results of a Prospective Study and Identification of New Strategies to Increase Traceability of Plasma-derived Medicines.

Authors:  Sheyda Najafi; Ali Vasheghani Farahani; Hedieh Keshavarz-Bahaghighat
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

Review 4.  “Go no Go” in plasma fractionation in the world’s emerging economies: still a question asked 70 years after the COHN process was developed!

Authors:  Thierry Burnouf; Jerard Seghatchian
Journal:  Transfus Apher Sci       Date:  2014-10       Impact factor: 1.764

5.  Evaluation of the confidential unit exclusion on Iranian blood donors: An 11-year experience.

Authors:  Mohammad Reza Ameli; Seyed Hossein Hosseini; Fariba Rad; Seyed Mehdi Sajjadi
Journal:  Asian J Transfus Sci       Date:  2021-06-12

6.  Overview of blood transfusion system of iran: 2002-2011.

Authors:  Am Cheraghali
Journal:  Iran J Public Health       Date:  2012-08-31       Impact factor: 1.429

7.  Cost effectiveness of Iran national plasma contract fractionation program.

Authors:  Abdol Majid Cheraghali
Journal:  Daru       Date:  2012-10-22       Impact factor: 3.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.